All In Biotech

Drug Trial Radar · NCT07105111

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

A Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Aug 29, 2025

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Aug 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

Conditions

  • Schizophrenia
  • Schizoaffective Disorder
  • Bipolar Disorder
  • Major Depressive Disorder
  • Tardive Dyskinesia

Interventions

  • ValbenazineDrug

    Valbenazine capsules for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score (AIMS 1-7) at Week 24Time frame: Baseline, Week 24

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Bryant, Arkansas · Recruiting

  • Neurocrine Clinical Site

    Chino, California · Recruiting

  • Neurocrine Clinical Site

    Fresno, California · Recruiting

  • Neurocrine Clinical Site

    Long Beach, California · Recruiting

  • Neurocrine Clinical Site

    Orange, California · Recruiting

  • Neurocrine Clinical Site

    Redlands, California · Recruiting

  • Neurocrine Clinical Site

    San Diego, California · Recruiting

  • Neurocrine Clinical Site

    Bonita Springs, Florida · Recruiting

  • Neurocrine Clinical Site

    Hialeah, Florida · Recruiting

  • Neurocrine Clinical Site

    Miami, Florida · Recruiting

  • Neurocrine Clinical Site

    Orange City, Florida · Recruiting

  • Neurocrine Clinical Site

    Port Charlotte, Florida · Recruiting

  • Neurocrine Clinical Site

    Tampa, Florida · Recruiting

  • Neurocrine Clinical Site

    Augusta, Georgia · Recruiting

  • Neurocrine Clinical Site

    Naperville, Illinois · Recruiting

  • Neurocrine Clinical Site

    Omaha, Nebraska · Recruiting

  • Neurocrine Clinical Site

    Independence, Ohio · Recruiting

  • Neurocrine Clinical Site

    Austin, Texas · Recruiting

  • Neurocrine Clinical Site

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.